07:17 AM EDT, 10/01/2024 (MT Newswires) -- Merck ( MRK ) said Tuesday it completed acquiring full global rights to an investigational antibody, CN201, from Curon Biopharmaceutical for about $750 million.

CN201 is currently being studied for potential treatment of two different types of leukemia, Merck ( MRK ) said.

The transaction's charge will be included in the company's Q3 non-GAAP results to be released at the end of October, Merck ( MRK ) added.

Price: 113.39, Change: -0.17, Percent Change: -0.15